Cbd news 2018

Here are some notable CBD news stories from 2018:

January 2018

• The FDA approves Epidiolex, a CBD-based medication, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy. (Source: FDA)

February 2018

• The DEA reclassifies CBD from Schedule I to Schedule V, making it easier to research and develop CBD-based products. (Source: DEA)

March 2018

• The Farm Bill, a federal law, is passed, allowing hemp cultivation and CBD production to be regulated by the USDA. (Source: USDA)

April 2018

• The FDA holds a public hearing to discuss the regulation of CBD and other cannabis-derived products. (Source: FDA)

May 2018

• The World Health Organization (WHO) publishes a report recommending that CBD be removed from the list of controlled substances. (Source: WHO)

June 2018

• The FDA approves a CBD-based medication, Epidiolex, for the treatment of tuberous sclerosis complex, a rare genetic disorder. (Source: FDA)

July 2018

• The European Union (EU) approves Epidiolex for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. (Source: EU)

August 2018

• The FDA sends warning letters to several companies for making false or unsubstantiated claims about their CBD products. (Source: FDA)

September 2018

• The FDA holds a public meeting to discuss the regulation of CBD and other cannabis-derived products. (Source: FDA)

October 2018

• The DEA announces that it will not reschedule CBD, keeping it as a Schedule I drug. (Source: DEA)

November 2018

• The FDA approves a CBD-based medication, Epidiolex, for the treatment of seizures associated with Lennox-Gastaut syndrome. (Source: FDA)

December 2018

• The FDA announces that it will hold a public hearing in 2019 to discuss the regulation of CBD and other cannabis-derived products. (Source: FDA)

These are just a few of the notable CBD news stories from 2018. The year saw significant progress in the regulation and acceptance of CBD, with the FDA approving several CBD-based medications and the DEA reclassifying CBD from Schedule I to Schedule V.